naphazoline (OTC)

Brand and Other Names:Privine
  • Print

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

nasal spray

  • 0.05% (20mL)

Nasal Decongestant

1-2 sprays per nostril q6hr PRN

Dosage Forms & Strengths

nasal spray

  • 0.05% (20mL)

Nasal Decongestant

< 12 years

  • Not recommended

>12 years

  • 1-2 sprays per nostril q6hr PRN
Next:

Interactions

Interaction Checker

and naphazoline

No Results

     activity indicator 
    No Interactions Found
    Interactions Found

    Contraindicated

      Serious - Use Alternative

        Significant - Monitor Closely

          Minor

            All Interactions Sort By:
             activity indicator 

            Contraindicated (0)

              Serious - Use Alternative (1)

              • iobenguane I 131

                naphazoline will decrease the level or effect of iobenguane I 131 by Other (see comment). Avoid or Use Alternate Drug. Based on the mechanism of action of iobenguane, drugs that reduce catecholamine uptake or that deplete catecholamine stores may interfere with iobenguane uptake into cells, and thus, reduce iobenguane efficacy. Discontinue interfering drugs for at least 5 half-lives before administration of either the dosimetry or an iobenguane dose. Do not administer these drugs until at least 7 days after each iobenguane dose.

              Monitor Closely (3)

              • nicotine intranasal

                naphazoline decreases levels of nicotine intranasal by Other (see comment). Use Caution/Monitor. Comment: Nasal vasoconstrictors prolong the time to peak concentrations by ~40% and decreases peak concentration by ~20%.

              • safinamide

                naphazoline and safinamide both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor. Monitor patients for hypertension if safinamide is prescribed concomitantly with prescription or nonprescription sympathomimetics, including nasal, oral, or ophthalmic decongestants and cold remedies.

              • solriamfetol

                naphazoline and solriamfetol both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.

              Minor (0)

                Previous
                Next:

                Adverse Effects

                Frequency Not Defined

                CNS (anxiety, dizziness, tremor, etc)

                Burning

                Stinging

                Sneezing

                Dryness

                Local irritation

                Rebound congestion

                Previous
                Next:

                Warnings

                Contraindications

                Heart disease (incr BP, HR, palpitations)

                Narrow angle glaucoma

                Cautions

                Caution in HTN, hyperthyroidism, ocular injury, DM, open-angle glaucoma

                Overuse may cause rebound congestion

                Previous
                Next:

                Pregnancy & Lactation

                Pregnancy Category: C

                Lactation: not known if excreted in breast milk

                Pregnancy Categories

                A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

                B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

                C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

                D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

                X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

                NA: Information not available.

                Previous
                Next:

                Pharmacology

                Mechanism of Action

                Alpha 1 adrenergic agonist; stimulates alpha-adrenergic receptors in nasal conjunctiva and arterioles to produce vasoconstriction that results in nasal decongestion

                Pharmacokinetics

                Absorption: minimal systemic

                Onset: 10 min

                Duration: 2-6 hr

                Previous
                Next:

                Images

                No images available for this drug.
                Previous
                Next:

                Patient Handout

                A Patient Handout is not currently available for this monograph.
                Previous
                Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.